Spectroscopic, Quantum Chemical, Docking, and Simulation Studies of a Benzothiazole‐Based Derivative With Anti‐Breast Cancer Potential
Chemistry & Biodiversity · 2026-02 · 23 (2)
DOI: 10.1002/cbdv.202502998 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemistry & Biodiversity, online erschienen am 03.02.2026. Verfasst von N Siva Jyothi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physics, Periyar Maniammai Institute of Science and Technology, Thanjavur, India. Hauptthemen laut MEDLINE: Benzothiazoles, Antineoplastic Agents, Molecular Docking Simulation, Breast Neoplasms. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 72 Literaturangaben.
Abstract (Originalsprache)
This work presents an integrated spectroscopic and theoretical investigation of 2‐(benzothiazolylthio)acetic acid (BTA). Experimental characterization was performed using FT‐IR, FT‐Raman, XRD, and UV–Vis techniques, while quantum chemical studies were carried out at the DFT/B3LYP/6‐311++G(d,p) level. The simulated XRD pattern and calculated vibrational frequencies agreed well with the experimental results, validating the molecular structure. Electronic features were explored using MEP mapping and Mulliken population analysis, which revealed charge distributions and reactive regions. UV–Vis absorption bands were examined experimentally and reproduced using TD‐DFT. NBO analysis identified intramolecular interactions supporting the molecule's bioactive potential. Hirshfeld surface analysis and fingerprint plots provided further insight into intra‐ and intermolecular contacts, while topological descriptors, including ELF, LOL, and RDG clarified bonding characteristics. Molecular docking studies against breast cancer‐related proteins revealed binding affinities ranging from −6.9 to −6.6 kcal/mol. Molecular dynamics simulations demonstrated stable ligand–protein complexes, and ADMET predictions indicated favorable pharmacokinetic and toxicity profiles. The cytotoxicity of BTA was evaluated using the MCF‐7 breast cancer cell line, yielding an IC 50 value of 14.15 µg/mL, which indicates favorable anticancer activity. Taken together, the combined spectroscopic, computational, docking, dynamics, and pharmacological findings highlight BTA as a promising anti‐breast cancer candidate, showing comparable potential to the standard drug anastrozole.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physics, Periyar Maniammai Institute of Science and Technology, Thanjavur, India.
- PG & Research Department of Physics, Thanthai Periyar Government Arts and Science College, Tiruchirappalli, India.
- Laboratory of Materials Chemistry and the Living: Activity & Reactivity (LCMVAR), Department of Chemistry, Faculty of Matter Sciences, University of Batna 1, Batna, Algeria.
- Department of Physics, Kalasalingam Academy of Research and Education, Krishnankoil, India.
ORCID-Profile: N Siva Jyothi, J Senthil Kumar, Abdelatif Messaoudi, S Sumathi, N Karthik, S Jeyavijayan
Zitieren
APA
Siva Jyothi, N., Senthil Kumar, J., Messaoudi, A., Sumathi, S., Karthik, N., & Jeyavijayan, S. (2026). Spectroscopic, Quantum Chemical, Docking, and Simulation Studies of a Benzothiazole‐Based Derivative With Anti‐Breast Cancer Potential. Chemistry & Biodiversity, 23(2). https://doi.org/10.1002/cbdv.202502998
Vancouver
Siva Jyothi N, Senthil Kumar J, Messaoudi A, Sumathi S, Karthik N, Jeyavijayan S. Spectroscopic, Quantum Chemical, Docking, and Simulation Studies of a Benzothiazole‐Based Derivative With Anti‐Breast Cancer Potential. Chemistry & Biodiversity. 2026;23(2). doi:10.1002/cbdv.202502998
BibTeX
@article{SivaJyothi2026,
author = {Siva Jyothi, N and Senthil Kumar, J and Messaoudi, Abdelatif and Sumathi, S and Karthik, N and Jeyavijayan, S},
title = {Spectroscopic, Quantum Chemical, Docking, and Simulation Studies of a Benzothiazole‐Based Derivative With Anti‐Breast Cancer Potential},
journal = {Chemistry & Biodiversity},
year = {2026},
volume = {23},
number = {2},
doi = {10.1002/cbdv.202502998}
}
EUVIMED